UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated.

The company has developed RTGel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained-release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option.

UroGen's lead product candidates, UGN-101 (mitomycin urothelial gel, known as MitoGel) and UGN-102 (mitomycin intravesical gel, known as VesiGel), are designed to potentially remove tumors by nonsurgical means and to treat several forms of non-muscle-invasive urothelial cancer, including low-grade upper-tract urothelial carcinoma and bladder cancer, respectively.

In April 2020, the FDA accepted for filing UroGen's new drug application for UGN-101 (mitomycin gel) for the treatment of low-grade upper-tract urothelial cancer. UGN-101 will be the only drug available for this type of cancer.